'Stealth' corporate innovation: an emerging threat for therapeutic drug development

01-nov-2019 | Revista: Nature Immunology

Dimitrios C Mastellos, Anna M Blom, E Sander Connolly, Mohamed R Daha, Brian V Geisbrecht, Berhane Ghebrehiwet, Piet Gros, George Hajishengallis, V Michael Holers, Markus Huber-Lang, Taroh Kinoshita, Tom E Mollnes, Robert A Montgomery, B Paul Morgan, Bo Nilsson, Ruben Pio, Daniel Ricklin, Antonio M Risitano, Ronald P Taylor, Alberto Mantovani, John P A Ioannidis, John D Lambris

Abstract

Therapeutic innovations of potentially great clinical impact should embrace the overarching values of research accountability, data transparency and validation through the scientific peer-review process.

CITA DEL ARTÍCULO Nat Immunol. 2019 Nov;20(11):1409-1413. doi: 10.1038/s41590-019-0503-1

ver publicación en pubmed

Nuestros autores

Dr. Rubén Pío Osés Ver Curriculum

Investigador | Investigador principal Grupo de Investigación en Oncología Traslacional